Recruiting

Observational Study

Sponsor:

AstraZeneca

Code:

NCT07606066

Conditions

Type 2 Diabetes

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Procedure: assessment

Study Details

Brief summary:

The purpose of this study is to identify and characterize patients with known Type 2 Diabetes Mellitus (T2DM) for possible participation in ongoing or future T2DM clinical studies, and to characterize trends in key concomitant medication use in this patient population across different geographical regions.

Conditions

Type 2 Diabetes

Study ID

NCT07606066

Start date

May 6, 2026

Status verified date

Mar, 2026

Completion date

Mar 31, 2027

Anticipated

Primary completion date

Mar 31, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Participants must be ≥ 18 years of age at the time of signing the ICF.
  • Patients with a diagnosis of T2DM, test- or documentation-confirmed as per World

Health Organization or local diagnostic standards, inadequately managed with:

1. Lifestyle management alone, AND/OR
2. A stable dose of background glucose-lowering medication(s) for T2DM (As specified in the Protocol) for at least 45 days prior to signing the ICF.

  • Expresses interest in participating in an ongoing or future T2DM clinical study, is motivated and willing to make themselves available for the duration of the study, and is able to follow study procedures as required.
  • Provision of signed and dated written informed consent (As specified in the Protocol) before any study-specific procedures, sampling, or analysis.

Exclusion Criteria:

  • Current or planned use of GLP-1 RAs prohibited in ongoing or future T2DM studies evaluating the efficacy and safety of investigational GLP-1 RAs (As specified in the Protocol).
  • Diagnosed with Type 1 diabetes mellitus.
  • Known pregnancy at the time of visit or having the intention to become pregnant.

Study Design

Enrollment

2150 participants

Anticipated

Interventions and Outcome Measures

Arms

Participants with Type 2 Diabetes

Participants with Type 2 Diabetes

Interventions

Procedure: assessment

The approximate volume of blood required is 2 mL

Primary outcome measure

  • Patient demographics [ Time Frame: Visit 1 (Single day) ]
  • Medical and surgical history [ Time Frame: Visit 1 (Single day) ]
  • Concomitant medication [ Time Frame: Visit 1 (Single day) ]
  • HbA1c levels [ Time Frame: Visit 1 (Single day) ]

Central Contacts and Locations

Central contacts

AstraZeneca Clinical Study Information Center

1-877-240-9479information.center@astrazeneca.com

Locations

Research Site

Recruiting

Little Rock, Arkansas, United States, 72205

Research Site

Recruiting

Lincoln, California, United States, 95648

Research Site

Recruiting

Lake City, Florida, United States, 32055

Research Site

Recruiting

Ocoee, Florida, United States, 34761

Research Site

Recruiting

Decatur, Georgia, United States, 30030

Research Site

Recruiting

Potomac, Maryland, United States, 20854

Research Site

Recruiting

Gaffney, South Carolina, United States, 29340

Research Site

Recruiting

Renton, Washington, United States, 98057

More Information

Sponsor

AstraZeneca

Last update posted

Aug 25, 2026

Last verified

Mar, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by AstraZeneca on 2026-08-25.